Journal ArticleOPEN ACCESS

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

  • Prince H
  • Geskin L
  • Akilov O
  • et al.
Blood (2022) 140(Supplement 1) 6577-6578
DOI: 10.1182/blood-2022-167564
N/ACitations
Citations of this article
2Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Prince, H. M. M., Geskin, L. J., Akilov, O. E., Kuzel, T. M., Querfeld, C., Ooi, C. E., … Foss, F. M. (2022). Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. Blood, 140(Supplement 1), 6577–6578. https://doi.org/10.1182/blood-2022-167564

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free